Newamsterdam Insider Kooij Buys 38,172 Shares at $10.90 — Signals Strong Confidence

Insider Activity Highlights a Strategic Accumulation

On January 23 2026, Chief Accounting Officer Kooij Louise Frederika executed a sizable purchase of 38,172 ordinary shares at an average price of $10.90, substantially below the market close of $32.63. The trade, disclosed in a Form 4 filing, represents a 5.1 % increase in her holdings, bringing her post‑transaction stake to 62,525 shares. This purchase follows a period of aggressive selling by Kooij earlier in January, when she liquidated more than 42,000 shares at prices ranging from $33.25 to $34.75. The timing suggests a deliberate shift from short‑term trading to a long‑term position, possibly signaling confidence in Newamsterdam’s near‑term milestones.

Market Context and Investor Implications

The buy signals that senior management may anticipate an upside in valuation, potentially tied to upcoming clinical data or regulatory approvals. Kooij’s recent accumulation coincides with a broader insider buying trend: Chief Financial Officer Somaiya Mayur Ian added 60,216 shares on January 20, while other executives have been steadily increasing their holdings. This alignment among senior leaders can reinforce market confidence, yet it also raises questions about liquidity. If insiders continue to buy while the stock remains below its 52‑week high, it could indicate that the company’s fundamentals—particularly its negative P/E of –17.21 and current volatility—are not yet fully reflected in the market price.

Patterns in Kooij’s Trading

Kooij’s transaction history illustrates a pattern of opportunistic selling at high price points followed by strategic buying at lower valuations. In December 2025 she sold 43,872 shares at $35.30, then repurchased 38,872 shares at $10.00 the same day, effectively locking in a substantial discount. Over the past few months she has executed multiple sell‑buy cycles, often trading options (right to buy) that expire in 2028. Her most recent sell on January 5 (2,647 shares at $33.25) preceded the large purchase on January 23, underscoring a classic “sell high, buy low” approach. This pattern suggests that Kooij is actively managing her exposure to the company’s share price movements rather than committing to a passive stake.

Strategic Implications for Newamsterdam

If senior executives continue to accumulate shares while the stock trades below its November high, the market may interpret this as a vote of confidence in Newamsterdam’s pipeline. The company’s focus on oral small‑molecule therapies for cardiovascular and metabolic diseases positions it well for a growing therapeutic area, but its negative earnings signal that profitability is still a few years away. Insider buying could help support the share price, potentially easing capital‑raising constraints and enabling further R&D investments. However, investors should monitor the timing of future insider trades—particularly large sells that could signal a reevaluation of risk—alongside the company’s clinical milestones to gauge whether the stock’s current valuation reflects its long‑term prospects.